386Rhythm Management6177124160MedSurg183150333283Operating income allocated to reportable segments438422821829Corporate expenses and currency exchange
(77)(71)(146)(155)Goodwill and other intangible asset impairment
charges; and acquisition-, divestiture-, restructuring-,
and litigation-related net charges and credits
(40)(3,839)(580)(3,869)Amortization expense(101)(99)(204)(195)Operating income (loss)$220$(3,587)$(109)$(3,390)*We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency and sales from divested businesses. Sales generated from reportable segments and divested businesses, as well as operating results of reportable segments and corporate expenses, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits. We restated segment information for the prior period based on standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuations. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to goodwill and other intangible asset impairment charges; acquisition-, divestiture-, restructuring- and litigation-related charges and credits; and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation above.** We have restated prior year information to conform t
|SOURCE Boston Scientific Corporation|
Copyright©2012 PR Newswire.
All rights reserved